Nova Science Publishers, New York, U.S.A has now released
Personalized Medicine (Beyond PET Biomarkers), which is an
extension of the authors recently published book Progress in PET
Radiopharmaceuticals: Quality Control and Theranostics. In addition
to recently-developed clinically-significant PET-RPs as biomarkers,
this book describes various other emerging biotechnologies
including: genomic medicine, nanotechnology, novel molecular
biomarkers, and noninvasive imaging biotechnologies for early
theranostics and personalised patient care, with minimum or no
adverse effects. New therapeutic interventions including gene and
cell therapies, pharmacogenomics, next generation sequencing,
genome-wide association studies, proteomics, metabolomics,
bioinformatics, systems biology complementing areas of
pharmacokinetics and pharmacodynamics, human investigations and
clinical trials, pharmacovigilance, pharmacoepidemiology, and
population pharmacology are some of the most significant
disciplines of predictive, precision, and personalised medicine
(PM) as described in this book. More specifically, different
sub-specialties of omics biotechnology including: genomic,
proteomic, glycomic, lipidomic, metabolomics, metalomic, and
microRNA biomarkers are described to accomplish early and
personalised theranostics of chronic illnesses with currently
limited therapeutic options and success. Recent advances in
nanotechnology and novel biomarkers to accomplish personalised
theranostics of chronic diseases including, but not limited to:
cancer, fetal alcohol syndrome, Alzheimers disease, Parkinsons
disease, vascular dementia, amyotrophic lateral sclerosis, and
multiple sclerosis. Usually, nanoparticles (NPs) are trapped in the
reticuloendothelial system (RES) comprising the lungs, liver, and
spleen. To prevent their entry into the RES system and enhance drug
targeting, stealth property of polyethylene glycol (PEG) as a
covalent linker is utilised. However, pegylation may reduce the
biological activity of the antibody or other labile molecule
attached to NPs. Therefore, positively-charged chitosans and
negatively charged alginates have been developed. Liposomal
encapsulated Doxorubicin (Adriamycin) was approved in the early
seventies for the treatment of breast cancer. In addition, enhanced
permeability and retention (EPR) property of newly synthesised
micro vessels of a hyper proliferating tumor is utilised to
selectively invade the cancer stem cells is intricately described.
Various noninvasive in-vivo imaging technologies including
computerised tomography (CT), magnetic resonance imaging (MRI)
along with magnetic-resonance spectroscopic (MRS) capability,
single photon emission tomography (SPECT), positron emission
tomography (PET), ultra sound alone or as hybrid images to obtain
precise 5D anatomical landmarks, regional physiology, and
biochemistry of the human body organs at cellular, molecular, and
genetic level in health and disease are described. The book also
describes in-vitro methods to acquire images of tissues and cells
in culture employing digital infrared imaging, digital fluorescence
microscopic, confocal microscopic, and fluorescence resonance
transfer (FRET) resonance imaging for detecting apoptosis and/or
necrosis at the cellular, molecular and genetic level. This
timely-released manuscript will attract basic scientists,
researchers, and physicians interested in further developing the
emerging concept of personalised medicine (PM), and will serve as a
textbook for Masters, M.D., and Ph. D students, and a reference
book for doctors, professors, basic researchers, scientists, and
general public. The author has explained recently-discovered novel
biomarkers for the personalised diagnosis and treatment of cancer,
cardiovascular diseases, neurodegenerative diseases, and other
chronic inflammatory diseases such as asthma, COPD, cystic
fibrosis, migraine, and rheumatoid arthritis to accomplish the long
quested goal of evidence-based personalised theranostics (EBPT).
Recently-discovered disease-specific biomarkers can be successfully
employed alone or in combination for the personalised treatment of
chronic multidrug-resistant illnesses. Particularly, progressive
neurodegenerative diseases such as fetal alcohol syndrome,
Parkinsons disease, drug addiction, Alzheimers disease, vascular
dementia, amyotrophic lateral sclerosis, and demyelinating relapse
and remission multiple sclerosis (RRMS) are described in detail
because personalised treatment of these devastating diseases is
currently a significant challenge. There are several other chronic
drug resistant pro-inflammatory and infectious diseases, which
could not be covered in sufficient detail owing to the lack of
expertise, time, and limited space allocated to write this
dedicated and clinically significant book. The author apologises to
the entire global scientific community for his own ignorance, and
humbly requests readers to go through the books interesting and
most recent contents to enhance their basic knowledge regarding
personalised medicine beyond PET biomarkers, which is one of the
most demanding disciplines of modern medicine.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
Welcome to Loot.co.za!
Sign in / Register |Wishlists & Gift Vouchers |Help | Advanced search
